SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Prices And Availability Of Biopharmaceuticals: An International Comparison
1 references·6 citing·24 second hop
Prices And Availability Of Biopharmaceuticals: An International Comparison (2006)Prices And Availability Of Biopharmaceuti…Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries (2003)Prices And Availability Of Ph…International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies (2021)International Prescription Dr…Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries? (2020)Uptake of Biosimilar Inflixim…Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues (2018)Differential Pricing of Pharm…Contemporary generic market in Japan – key conditions to successful evolution (2014)Contemporary generic market i…Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement (2011)Pharmaceutical Pricing in Eme…Drug Pricing and Value in Oncology (2010)Drug Pricing and Value in Onc…Does Regulation Drive Out Competition in Pharmaceutical Markets? (2000)Experts' agency problems: evidence from the prescription drug market in Japan (2007)Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease (2008)The Key Role of the Leading Emerging Bric Markets in the Future of Global Health Care (2014)Global pharmaceutical regulation: the challenge of integration for developing states (2016)A Contribution to the Theory of Taxation (1927)Cross-national price differences for pharmaceuticals: how large, and why? (2000)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Financial incentives and physicians’ prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan (2008)Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States (2014)Methods for the Economic Evaluation of Health Care Programmes (2005)Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context (2012)A Theory of Oligopoly (1964)Price Discrimination and Social Welfare (2000)Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry (1991)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)What do we know about entry? (1995)The economics of biosimilars. (2013)The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India (2015)Key drivers for market penetration of biosimilars in Europe (2017)Evidence-based public policy making for medicines across countries: findings and implications for the future (2021)International Prices And Availability Of Pharmaceuticals In 2005 (2008)National Health Expenditure Projections, 2018–27: Economic And Demographic Trends Drive Spending And Enrollment Growth (2019)
this work references cited by second hop

References

  • 2003Prices And Availability Of Pharmaceuticals: Evidence From Nine Countries199 cited

Cited by

  • 2018Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues64 cited
  • 2014Contemporary generic market in Japan – key conditions to successful evolution61 cited
  • 2010Drug Pricing and Value in Oncology61 cited
  • 2020Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?57 cited
  • 2021International Prescription Drug Price Comparisons: Current Empirical Estimates and Comparisons with Previous Studies56 cited
  • 2011Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement56 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work